Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Provides Corporate Update
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Jefferies Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Streamlined Clinical Alignment
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Highlights 2022 Accomplishments and Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS